Latest Breaking News On - Astex therapeutics - Page 1 : comparemela.com

TAR-210 results show 90 percent recurrence-free survival

Updated results reinforce the potential of TAR-210 to transform treatment of non-muscle-invasive bladder cancer with fibroblast growth factor receptor.

Comunidad autonoma de catalunaRegion flamandeSan antonioUnited statesEurop urolJanssen pharmaceuticaTanakam sonpavdeClin pharmacolSabine brookmanHenar heviaIndianj urolAstex therapeuticsDrug administrationEuropean medicines agencyNone of janssen cilag internationalEuropean society for medical oncology

AstraZeneca s Truqap plus Faslodex receives CHMP recommendation for advanced breast cancer

AstraZeneca s Truqap plus Faslodex receives CHMP recommendation for advanced breast cancer
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

Susan galbraithCommittee for medicinal products human useEuropean medicines agencyMedicinal productsHuman useAstex therapeutics

Truqap recommended for EU breast cancer approval | Company Announcement

Investegate announcements from Truqap recommended for EU breast cancer approval

United kingdomDaiichi sankyoAdrian kempAstrazeneca truqapMerck co incCommittee for medicinal products human useNational cancer instituteEnd results programInstitute of cancer researchEuropean medicines agencyWorld health organizationInvestor relations teamCancer research technologyEuropean unionNational comprehensive cancer networkZeneca truqap

Truqap plus Faslodex recommended for approval in the EU by CHMP for patients with advanced ER-positive breast cancer

AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been recommended for approval in the European Union (EU) for the treatment of adult patients with estrogen receptor (ER)-positive, HER2‑negative locally advanced or metastatic breast cancer with one or more PIK3CA, AKT1, or .

United kingdomAstrazeneca truqapDaiichi sankyoCancer research technologyCommittee for medicinal products human useWorld health organizationInvestor relations teamNational comprehensive cancer networkEuropean medicines agencyInstitute of cancer researchMerck co incEuropean unionNational cancer instituteEnd results programMedicinal productsHuman use

AstraZeneca Truqap plus Faslodex gets nod in Japan for advanced HR-positive breast cancer

Cambridge: AstraZeneca s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in Japan for the treatment of adult patients with unresectable or recurrent PIK3CA, AKT1, or.

Dave fredricksonJapanese ministry of healthEuropean unionInfectious diseases centerCancer research technologyInstitute of cancer researchJapanese ministryNew england journalTokyo metropolitan cancerKomagome hospitalExecutive vice presidentOncology business unitAstex therapeuticsCancer researchCancer research technology limited